CARE™ Needs Assessment: CAR T in Lymphoma
The approval of CAR T therapies in Canada has changed the treatment landscape of B-cell non-Hodgkin’s lymphoma (NHL). This questionnaire aims to identify current practice patterns and needs relating to uptake and incorporation of CAR T agents within practice. The results of this assessment will be shared back and harnessed to inform development of subsequent CARE™ education programs, including CARE™ CAR T Guidance and localized content. Thank you in advance for completing this questionnaire, your insights are valuable. Peter Anglin, MD, FRCPC, MBA (CARE™ Hematology Steering Faculty)
19Questions